Dimple Chakravarty

Title: Dimple Chakravarty: Innovator in Prostate Cancer Research

Introduction

Dimple Chakravarty is a prominent inventor based in New York, NY (US). She has made significant contributions to the field of cancer research, particularly in the diagnosis and treatment of prostate cancer. Her innovative work has the potential to improve patient outcomes and advance therapeutic strategies.

Latest Patents

Dimple Chakravarty holds a patent for her invention titled "NEAT1 as a prognostic marker and therapeutic target for prostate cancer." This invention relates to the diagnosis and prognosis of prostate cancer, as well as therapeutic treatment options. Specifically, it provides diagnostic and prognostic methods based on detecting nuclear enriched abundant transcript 1 (NEAT1) levels in a sample. Furthermore, the invention outlines methods for treating prostate cancer by targeting NEAT1 through interfering RNA. She has 1 patent to her name.

Career Highlights

Dimple Chakravarty is affiliated with Cornell University, where she conducts her research and contributes to the academic community. Her work is recognized for its impact on understanding prostate cancer and developing new therapeutic approaches.

Collaborations

Dimple collaborates with Mark A Rubin, who is also involved in cancer research. Their partnership enhances the research efforts aimed at improving cancer diagnosis and treatment.

Conclusion

Dimple Chakravarty is a trailblazer in the field of prostate cancer research, with her innovative patent offering new insights into diagnosis and treatment. Her contributions are vital for advancing medical science and improving patient care.